AI summary · may contain errors
Fumarate hydratase (FH) deficiency in clear cell renal cell carcinoma (ccRCC) drives fumarate accumulation that remodels the ubiquitinated proteome and increases ferroptosis resistance.
- Open access
Moving in European Urology, Journal for ImmunoTherapy of Cancer, Annals of Oncology, Cell Death & Differentiation, Clinical Cancer Research, Journal of Clinical Investigation, Nature Reviews Clinical Oncology and Nature Reviews Disease Primers.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Fumarate hydratase (FH) deficiency in clear cell renal cell carcinoma (ccRCC) drives fumarate accumulation that remodels the ubiquitinated proteome and increases ferroptosis resistance.
AI summary · may contain errors
High midkine (MDK) expression in clear cell renal cell carcinoma (ccRCC) is linked to advanced stage, aggressive histology, and worse survival, defining a Treg-enriched immune-evasive phenotype.
AI summary · may contain errors
Lower anterior access single-port robotic radical nephroureterectomy in 47 patients with upper tract urothelial carcinoma achieved a 76.7% 12-month pentafecta rate with 6% grade ≥3 complications.
AI summary · may contain errors
In 1049 patients with renal cell carcinoma and brain metastases treated from 2016–2022, median overall survival was 20·0 months and varied widely by updated Renal GPA.
AI summary · may contain errors
Elevated TARBP2 expression in renal cell carcinoma is linked to poor prognosis and immune checkpoint blockade resistance, and it promotes immune escape by upregulating B7-H3.
AI summary · may contain errors
Panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma achieved a 53.9% objective response rate, including 15.4% complete responses, across 26 patients.
AI summary · may contain errors
Renal tumor biopsy in renal cell carcinoma yields a pooled diagnostic yield of 90%, with sensitivity of 99% and specificity of 85% for malignancy.
AI summary · may contain errors
In IMmotion010 high-risk localized renal cell carcinoma, matched primary and recurrent tumors show recurrence-linked shifts in proliferation, fatty acid synthesis, stromal biology, and immune programs, including MHC-I downregulation after adjuvant atezolizumab.
AI summary · may contain errors
CircLAMA5 (hsa_circ_0061093) is upregulated in sunitinib-resistant ccRCC models and promotes resistance by trapping Sam68 in the cytoplasm.
AI summary · may contain errors
Adjuvant pembrolizumab after surgery in high-recurrence clear cell renal cell carcinoma shows sustained disease-free survival benefit (HR 0.71) and improved overall survival (HR 0.66) at 5 years.
AI summary · may contain errors
Immune hub genes CCR5, CSF1R, CD86, CD8A, and LCP2 are upregulated in clear cell renal cell carcinoma and form a ccRCC-linked M03 immune module.
AI summary · may contain errors
MiT/TFE transcription factors are central regulators of lysosomal function, mTORC1 signaling, and cellular metabolism, and their dysregulation is increasingly recognized as a key driver of kidney cancer.
AI summary · may contain errors
Adding belzutifan or quavonlimab to pembrolizumab plus lenvatinib in previously untreated advanced clear-cell renal-cell carcinoma did not improve PFS or OS.
AI summary · may contain errors
Belzutifan plus lenvatinib improved progression-free survival in advanced clear-cell renal-cell carcinoma after anti-PD-(L)1 therapy, with HR 0.74 at final LITESPARK-011 analysis.
AI summary · may contain errors
Pathogenic variants in the folliculin (FLCN) gene are linked to Birt-Hogg-Dubé syndrome, which features benign skin tumors, renal neoplasia, cystic lung disease, and pneumothorax risk.
AI summary · may contain errors
A hyper-methylated DNA methylation subtype in metastatic clear cell renal cell carcinoma accounts for 15% of tumors and is linked to shorter overall survival.
Journals this month
Topics moving, week to 17 Nov 2026
By field